Urgent.News

What's breaking now, across thousands of outlets.

Tuesday, 1 September 2026 Reading Room

Health & Medicine

Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest

Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut annualized relapse rates (ARR) ...

endpoints.news ·

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

Rwanda: Curriculum Review Targets Gaps in Sexuality Education

[New Times] Curriculum developers are reviewing comprehensive sexuality education (CSE) in schools to make it more age-appropriate, inclusive and effective as teenage pregnancies remain a growing…

  • Rwanda's education board reviewing sexuality education curriculum.
  • Teenage pregnancies rose from 5% to 8% in three years.
  • Review aims to address misinformation and include disabled learners.

·allafrica.com

More from Tuesday 1 September →